CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level—may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition–induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 1×
“Furthermore, a persistently elevated rate of FFA oxidation generates reactive oxygen species in excess of scavenging capacity (42); the resulting oxidative stress contributes to mitochondrial damage in a range of pathologies (43).”
BackgroundESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907 · cited 1×
“perfusion injury (53)dconverge on insufficient mitochondrial energy output and contractile failure as the basic mechanism.”
BackgroundESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048 · cited 1×
“and functional manifestation (reduced or preserved ejection fraction) (51).”
Background
Cited by
Items 101–200 of 1,000
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Pabel, S., Hamdani, N., Luedde, M., & Sossalla, S. T. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00529-8 · Cited by 152
SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback
Upadhyay, A. (2024) · Kidney360 · doi:10.34067/kid.0000000000000425 · Cited by 167
“While Keap1-Nrf2 activation may increase GFR without affecting intraglomer-ular pressure, 80 more mechanistic studies are needed to better understand how SGLT2 inhibitor ’ s effect on Keap1-Nrf2 system modulates its effect on glomerular hemodynamics through TGF.”
BackgroundInfluentialEvolving Concepts of Myocardial Energy Metabolism: More Than Just Fats and Carbohydrates
Lopaschuk, G. D., & Ussher, J. R. (2016) · Circulation Research · doi:10.1161/circresaha.116.310078 · Cited by 139
Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
Marton, A., Kaneko, T., Kovalik, J., Yasui, A., Nishiyama, A., Kitada, K., & Titze, J. M. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00350-x · Cited by 141
Empagliflozin’s Fuel Hypothesis: Not so Soon
Lopaschuk, G. D., & Verma, S. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.018 · Cited by 143
“It has been hypothesized that empagliflozin may optimize cardiac energy metabolism, and that by improving myocardial energeticsandsubstrate efficiency, empagliflozin may reduce cardiac failure (the ‘‘fuel hypothesis’’) (Ferrannini et al., 2016; Mudaliar et al., 2016).”
BackgroundInfluentialChowdhury, B., Luu, A. Z., Luu, V. Z., Kabir, M. G., Pan, Y., Teoh, H., Quan, A., Sabongui, S., Al-Omran, M. A., Bhatt, D. L., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.015 · Cited by 134
SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
Maejima, Y. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00186 · Cited by 142
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
Li, J., Neal, B., Perkovic, V., de Zeeuw, D., Neuen, B. L., Arnott, C., Simpson, R., Oh, R., Mahaffey, K. W., & Heerspink, H. J. L. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.051 · Cited by 130
Oshima, H., Miki, T., Kuno, A., Mizuno, M., Sato, T., Tanno, M., Yano, T., Nakata, K., Kimura, Y., Abe, K., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.253666 · Cited by 137
“Recently, the myocardial fuel hypothesis for cardioprotection afforded by SGLT2 inhibitors has received attention (Ferrannini et al., 2016b; Mudaliar et al., 2016) because SGLT2 inhibitors increase blood b-hydroxybutyrate (bOHB) levels (Ferrannini et al., 2016a; Min et al., 2018).”
BackgroundLower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Suissa, S. (2018) · Diabetes Care · doi:10.2337/dc17-1223 · Cited by 129
Hundertmark, M., Adler, A., Antoniades, C. A., Coleman, R. L., Griffin, J. L., Holman, R. R., Lamlum, H., Lee, J., Massey, D., Miller, J. J. J. J., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062021 · Cited by 133
Connelly, K. A., Zhang, Y., Visram, A., Advani, A., Batchu, S. N., Desjardins, J.-F., Thai, K., & Gilbert, R. E. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.010 · Cited by 120
Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
Gao, Y.-M., Feng, S., Wen, Y., Tang, T., Wang, B., & Liu, B. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104215 · Cited by 131
Fadini, G. P., Bonora, B. M., Zatti, G., Vitturi, N., Iori, E., Marescotti, M. C., Albiero, M., & Avogaro, A. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0529-3 · Cited by 119
Fuchigami, A., Shigiyama, F., Kitazawa, T., Okada, Y., Ichijo, T., Higa, M., Hiyoshi, T., Inoue, I., Iso, K., Yoshii, H., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0977-z · Cited by 133
Therapeutic Advances in Diabetic Nephropathy
Sawaf, H., Thomas, G., Taliercio, J. J., Nakhoul, G., Vachharajani, T. J., & Mehdi, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020378 · Cited by 130
Perry, R. J., & Shulman, G. I. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.008387 · Cited by 147
DECLARE‐TIMI 58: Participants’ baseline characteristics
Raz, I., Mosenzon, O., Bonaca, M. P., Cahn, A., Kato, E. T., Silverman, M. G., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13217 · Cited by 117
State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications
Vallon, V. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae092 · Cited by 138
Bonora, B. M., Avogaro, A., & Fadini, G. P. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13012 · Cited by 118
“Notably, a mild metabolic shift to fatty substrate utilisation may not necessarily be harmful, and it has been proposed as one mechanism leading to the observed cardiovascular protection in the EMPA-REG Outcome trial (15).”
BackgroundKetogenic diet in endocrine disorders: Current perspectives
Gupta, L., Khandelwal, D., Kalra, S., Gupta, P., Dutta, D., & Aggarwal, S. (2017) · Journal of Postgraduate Medicine · doi:10.4103/jpgm.jpgm_16_17 · Cited by 112
“[19,20] Studies have shown that it prevents ischemic tissue damage in animal models undergoing either myocardial infarctions or stroke, leading to dramatically smaller ischemic/ necrotic lesion area.”
Prattichizzo, F., De Nigris, V., Micheloni, S., La Sala, L., & Ceriello, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13488 · Cited by 116
“This elimination is accompanied by an increased excretion of uric acid, a decrease in insulin release, and an increase in mean levels of ketone bodies such as β-hydroxybutyrate (BHB).(13) Immune cells secrete IL-1β in response to glucose spikes, insulin action and high uric acid concentrations,(61,65) while BHB inhibi…”
BackgroundResultInfluentialCardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Elrakaybi, A., Laubner, K., Zhou, Q., Hug, M. J., & Seufert, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101549 · Cited by 124
Dato, V. A., Lange, S., & Cho, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021211 · Cited by 125
“In murine and porcine models, it was recently found that SGLT2 inhibition increases cardiac ketone oxidation [98,99], ameliorating cardiac dysfunction by providing the heart with a more oxygen-efficient substrate than FAO [100,101].”
BackgroundManagement of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 125
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
Huang, K., Luo, X., Liao, B., Li, G., & Feng, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01816-5 · Cited by 126
Cardiac ketone body metabolism
Kadir, A. A., Clarke, K., & Evans, R. D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165739 · Cited by 121
Giugliano, D., Longo, M., Scappaticcio, L., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01430-3 · Cited by 107
Tsai, W.-H., Chuang, S.-M., Liu, S.-C., Lee, C.-C., Chien, M.-N., Leung, C.-H., Liu, S.-J., & Shih, H.-M. (2021) · Scientific Reports · doi:10.1038/s41598-021-94945-4 · Cited by 113
Salah, H. M., Al'Aref, S. J., Khan, M. S., Al-Hawwas, M., Vallurupalli, S., Mehta, J. L., Mounsey, J. P., Greene, S. J., McGuire, D. K., Lopes, R. D., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.10.064 · Cited by 110
Kawasoe, S., Maruguchi, Y., Kajiya, S., Uenomachi, H., Miyata, M., Kawasoe, M., Kubozono, T., & Ohishi, M. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0125-x · Cited by 109
SGLT2 Inhibitors: Benefit/Risk Balance
Scheen, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0789-4 · Cited by 119
SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
Filippatos, T. D., Liontos, A., Papakitsou, I., & Elisaf, M. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1581971 · Cited by 117
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.008 · Cited by 127
Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Kaplan, A., Abidi, E., EL‐Yazbi, A. F., Eid, A. H., Booz, G. W., & Zouein, F. A. (2018) · Heart Failure Reviews · doi:10.1007/s10741-017-9665-9 · Cited by 114
Effects of glycaemic management on diabetic kidney disease
MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i5.172 · Cited by 118
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
Tang, J., Ye, L., Yan, Q., Zhang, X., & Wang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.800490 · Cited by 120
Packer, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13229 · Cited by 100
Selvaraj, S., Fu, Z., Jones, P. G., Kwee, L. C., Windsor, S. L., Ilkayeva, O., Newgard, C. B., Margulies, K. B., Husain, M., Inzucchi, S. E., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060402 · Cited by 105
Function and mechanism of histone β-hydroxybutyrylation in health and disease
Zhou, T., Cheng, X., He, Y., Xie, Y., Xu, F., Xu, Y., & Huang, W. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.981285 · Cited by 129
Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
Maruyama, T., Takashima, H., Oguma, H., Nakamura, Y., Ohno, M., Utsunomiya, K., Furukawa, T., Tei, R., & Abe, M. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0212 · Cited by 103
Chatterjee, P., Fernando, M. G., Fernando, B., Dias, C. B., Shah, T. M., Silva, R., Williams, S., Pedrini, S., Hillebrandt, H., Goozee, K. G., et al. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111209 · Cited by 112
“…LDL-C and triglycerides when coconut oil consumption is compared to the consumption of other oils rich in unsaturated fats (Cox et al., 1995, 1998; Fisher et al., 1983; Heber et al., 1992; Mendis and Kumarasundaram, 1990; Mendis et al., 2001; Voon et al., 2011; WallMedrano et al., 2017).”
BackgroundHeart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
Fitchett, D. H., Udell, J. A., & Inzucchi, S. E. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.633 · Cited by 102
SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
Saucedo‐Orozco, H., Voorrips, S. N., Yurista, S. R., de Boer, R. A., & Westenbrink, B. D. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.1.1 · Cited by 114
Packer, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1732 · Cited by 105
Yoneda, M., Honda, Y., Ogawa, Y., Kessoku, T., Kobayashi, T., Imajo, K., Ozaki, A., Nogami, A., Taguri, M., Yamanaka, T., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001990 · Cited by 99
Therapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 108
Treatment approach to type 2 diabetes: Past, present and future
Blaslov, K., Naranđa, F. S., Kruljac, I., & Renar, I. P. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i12.209 · Cited by 113
Andreadou, I., Bell, R. M., Bøtker, H. E., & Zuurbier, C. J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165770 · Cited by 105
“The amelioration of myocardial injury appears not be to be through favorable shifts in metabolism, as has previously been suggested in the “Thrifty Substrate Hypothesis” [22]; protection can be elicited in hearts from pre-treated animals in whom ex-vivo perfusion provides only glucose as an energy substrate, and moreo…”
BackgroundCardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.009 · Cited by 92
Esterline, R. L., Vaag, A., Oscarsson, J., & Vora, J. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0832 · Cited by 98
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
Cinti, F., Moffa, S., Impronta, F., Cefalo, C. M. A., Sun, V. A., Sorice, G. P., Mezza, T., & Giaccari, A. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s114932 · Cited by 91
Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte
Filardi, T., Ghinassi, B., Baldassarre, A. D., Tanzilli, G., Morano, S., Lenzi, A., Basili, S., & Crescioli, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133299 · Cited by 98
Ketones can become the major fuel source for the heart but do not increase cardiac efficiency
Ho, K. L., Karwi, Q. G., Wagg, C. S., Zhang, L., Vo, K., Altamimi, T., Uddin, G. M., Ussher, J. R., & Lopaschuk, G. D. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa143 · Cited by 96
Obesity and the kidney: mechanistic links and therapeutic advances
Yau, K., Kuah, R., Cherney, D. Z. I., & Lam, T. K. T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00951-7 · Cited by 91
“…‘thrifty substrate’ hypothesis, which postulates that ketogenesis induced by SGLT2is alters metabolism to utilize β-hydroxybutyrate instead of fatty acids as an oxidation substrate in the heart and kidney, thereby improving oxygen consumption efficiencies and mediating cardioprotective effects 72 .”
Mima, A. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.04.011 · Cited by 94
Karwi, Q. G., Zhang, L., Wagg, C. S., Wang, W., Ghandi, M., Thai, D. L., Yan, H., Ussher, J. R., Oudit, G. Y., & Lopaschuk, G. D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0806-4 · Cited by 94
What does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition
Rieg, J. A. D., & Rieg, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13630 · Cited by 93
“This could lead to improved myocardial energetics and substrate efficiency, which consequently could improve cardiac efficiency and cardiac output.(87,88) A novel link between SGLT2 and sodium-hydrogen exchanger isoform 1 in the heart has been postulated to reduce cytoplasmic Na and Ca,(89)”
BackgroundNakatsu, Y., Kokubo, H., Bumdelger, B., Yoshizumi, M., Yamamotoya, T., Matsunaga, Y., Ueda, K., Inoue, Y., Inoue, M.-K., Fujishiro, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081704 · Cited by 89
Ranjan, A., Schmidt, S., Damm-Frydenberg, C., Steineck, I., Clausen, T. R., Holst, J. J., Madsbad, S., & Nørgaard, K. (2017) · Diabetes Care · doi:10.2337/dc16-1472 · Cited by 89
Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure
Dietl, A., & Maack, C. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0347-7 · Cited by 90
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
Martens, P., Mathieu, C., & Verbrugge, F. H. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0522-x · Cited by 99
Novel Diabetes Drugs and the Cardiovascular Specialist
Sattar, N. A., Petrie, M. C., Zinman, B., & Januzzi, J. L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.014 · Cited by 92
Santos‐Gallego, C. G., Requena-Ibáñez, J. A., Picatoste, B., Fardman, B., Ishikawa, K., Mazurek, R., Pieper, M. P., Sartori, S., Rodríguez‐Capitán, J., Fuster, V., et al. (2023) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.123.015298 · Cited by 87
Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Schönberger, E., Mihaljević, V., Steiner, K., Šarić, S., Kurevija, T., Majnarić, L. T., Bilić-Čurčić, I., & Canecki-Varžić, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20176671 · Cited by 93
β-Hydroxybutyrate as an epigenetic modifier: Underlying mechanisms and implications
He, Y., Cheng, X., Zhou, T., Li, D., Peng, J., Xu, Y., & Huang, W. G. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21098 · Cited by 94
“In addition to these elements, it has been suggested that the therapeutic effect of SGLT-2 inhibitors is related to elevated serum BHB levels [57].”
BackgroundPacker, M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa064 · Cited by 86
Carluccio, E., Biagioli, P., Reboldi, G., Mengoni, A., Lauciello, R., Zuchi, C., D’Addario, S., Bardelli, G., & Ambrosio, G. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01970-w · Cited by 85
“This latter effect tends to be compensated by oxidation of ketone bodies that are the most energetically efficient fuel because of the higher number of ATP molecules produced at the lowest oxygen requirements [29, 30].”
BackgroundLiu, H., Sridhar, V. S., Boulet, J., Dharia, A., Khan, A. A., Lawler, P. R., & Cherney, D. Z. I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154918 · Cited by 90
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.015 · Cited by 83
Kosiborod, M., Birkeland, K. I., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Jørgensen, M. E., Wittbrodt, E. T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13299 · Cited by 82
“6 11 A metabolic hypothesis has also been proposed, suggesting that a shift in myocardial metabolism from glucose and free fatty acids to ketones may contribute to the cardiovascular benefits of SGLT-2i.”
BackgroundThe Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Patel, D. K., & Strong, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00686-z · Cited by 79
Inzucchi, S. E., Fitchett, D., Jurišić‐Eržen, D., Woo, V., Hantel, S., Janista, C., Kaspers, S., George, J. T., Zinman, B., & on behalf of the EMPA‐REG OUTCOME® Investigators (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13938 · Cited by 82
Joubert, M., Manrique, A., Cariou, B., & Prieur, X. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.07.003 · Cited by 81
Towards precision medicine in heart failure
Weldy, C. S., & Ashley, E. A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00566-9 · Cited by 89
Kashiwagi, A., & Maegawa, H. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12644 · Cited by 82
Heart failure with preserved ejection fraction: current management and future strategies
Tschöpe, C., Birner, C. M., Böhm, M., Bruder, O., Frantz, S., Luchner, A., Maier, L. S., Störk, S., Kherad, B., & Laufs, U. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1170-6 · Cited by 87
“inhibitors, β-hydroxybutyrate is freely taken up by the heart and oxidized in preference to fatty acids [103].”
BackgroundPrattichizzo, F., de Candia, P., & Ceriello, A. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154799 · Cited by 82
Chen, X., Hocher, C., Shen, L., Krämer, B. K., & Hocher, B. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00177.2023 · Cited by 84
Ketones and the cardiovascular system
Lopaschuk, G. D., & Dyck, J. R. B. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00259-1 · Cited by 86
Baker, H. E., Kiel, A. M., Luebbe, S. T., Simon, B. R., Earl, C. C., Regmi, A., Roell, W. C., Mather, K. J., Tune, J. D., & Goodwill, A. G. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0733-2 · Cited by 79
Ketone metabolism in the failing heart
Lopaschuk, G. D., Karwi, Q. G., Ho, K. L., Pherwani, S., & Ketema, E. B. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158813 · Cited by 87
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01575-9 · Cited by 83
The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
Fattah, H., & Vallon, V. (2018) · Drugs · doi:10.1007/s40265-018-0901-y · Cited by 75
Shi, X., Verma, S., Yun, J., Brand‐Arzamendi, K., Singh, K. K., Liu, X., Garg, A., Quan, A., & Wen, X. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3018-9 · Cited by 76
Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy
Choksey, A., & Timm, K. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010441 · Cited by 76
Rajpal, A., & Ismail‐Beigi, F. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14080 · Cited by 70
Energy metabolism disorders and potential therapeutic drugs in heart failure
He, Y., Huang, W., Zhang, C., Chen, L., Xu, R., Li, N., Wang, F., Han, L., Yang, M., & Zhang, D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.007 · Cited by 84
Lorenzo-Almorós, A., Cepeda-Rodrigo, J. M., & Lorenzo, Ó. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.10.012 · Cited by 93
SGLT2 inhibitors: are they safe?
Filippas-Ntekouan, S., Filippatos, T. D., & Elisaf, M. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1394152 · Cited by 80
Tamargo, J. L. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.34.2 · Cited by 74
Sharma, A., & Verma, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.09.003 · Cited by 65
Papadopoulou, E., Loutradis, C., Tzatzagou, G., Kotsa, K., Zografou, I., Minopoulou, I., Theodorakopoulou, M. P., Τσάπας, Α., Karagiannis, A. I., & Sarafidis, P. A. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002690 · Cited by 74
Myocardial Ketones Metabolism in Heart Failure
Karwi, Q. G., Biswas, D., Pulinilkunnil, T., & Lopaschuk, G. D. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.04.005 · Cited by 75
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Blais, J., Li, Q., Jardine, M. J., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.06.018 · Cited by 70
Zhou, Y., & Wu, W. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000475942 · Cited by 70
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
Brown, E. E., Wilding, J. P. H., Alam, U., Barber, T. M., Karalliedde, J. J., & Cuthbertson, D. J. (2021) · Annals of Medicine · doi:10.1080/07853890.2020.1841281 · Cited by 80
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Chen, S., Wang, Q., Bakker, D., Hu, X. Y., Zhang, L., van der Made, I., Tebbens, A. M., Kovácsházi, C., Giricz, Z., Brenner, G. B., et al. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01067-9 · Cited by 73
Metadata
- Authors
- Ferrannini, E., Mark, M., & Mayoux, E.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Ferrannini, Ele
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-11
- Volume
- 39
- Issue
- 7
- Pages
- 1108-1114
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2412800896
- Cited by
- 975
- References
- 77
- Citations by year
- 2026: 53 · 2025: 53 · 2024: 73 · 2023: 79 · 2022: 91 · 2021: 134 · 2020: 114 · 2019: 100 · 2018: 110 · 2017: 119 · 2016: 47
- FWCI
- 125.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, EMPA-REG OUTCOME trial, cardioprotection, type 2 diabetes, hyperketonemia, beta-hydroxybutyrate, mitochondrial oxygen consumption, hemoconcentration, heart failure, cardiovascular mortality, diabetic heart disease
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucosides, Heart, Humans, Hypoglycemic Agents, Models, Biological, Research Design, Treatment Outcome, 3-Hydroxybutyric Acid, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.